DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity.
OBJECTIVE:Dipeptidyl-peptidase 4 (DPP-4) cleaves and inactivates the insulinotropic hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide, collectively termed incretins. DPP-4 inhibitors entered clinical practice as approved therapeutics for type-2 diabetes in 2006. However, in...
Main Authors: | Anja Böhm, Robert Wagner, Fausto Machicao, Jens Juul Holst, Baptist Gallwitz, Norbert Stefan, Andreas Fritsche, Hans-Ulrich Häring, Harald Staiger |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5531535?pdf=render |
Similar Items
-
Dissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humans
by: Martin Heni, et al.
Published: (2015-12-01) -
Gene x Gene Interactions Highlight the Role of Incretin Resistance for Insulin Secretion
by: Benjamin Assad Jaghutriz, et al.
Published: (2019-02-01) -
Clinical Use of DPP-4 Inhibitors
by: Baptist Gallwitz
Published: (2019-06-01) -
Polymorphism rs11085226 in the gene encoding polypyrimidine tract-binding protein 1 negatively affects glucose-stimulated insulin secretion.
by: Martin Heni, et al.
Published: (2012-01-01) -
Common genetic variation in the SERPINF1 locus determines overall adiposity, obesity-related insulin resistance, and circulating leptin levels.
by: Anja Böhm, et al.
Published: (2012-01-01)